Examining the Effects of Estradiol on Neural and Molecular Response to Reward

PHASE4RecruitingINTERVENTIONAL
Enrollment

103

Participants

Timeline

Start Date

April 20, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions
DepressionPsychosisAnhedonia
Interventions
DRUG

Transdermal Estradiol

Participants will be randomized to receive transdermal estradiol (100μg/day) patch for 3 weeks.

DRUG

Micronized Progesterone

Participants will receive an additional week of micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.

DRUG

Matching Placebo Patch

Participants will be randomized to receive a transdermal estradiol-matching placebo patch for 3 weeks

DRUG

Raclopride C11

All Participants will receive two PET-MR scans using \[11C\]raclopride IV as the tracer. The first scan will occur at baseline and the second at post treatment after 3 weeks.

Trial Locations (1)

27514

RECRUITING

University of North Carolina at Chapel Hill, Chapel Hill

All Listed Sponsors
collaborator

National Institute of Mental Health (NIMH)

NIH

lead

University of North Carolina, Chapel Hill

OTHER